past
decad
microbiolog
infecti
diseas
research
undergon
profound
revolut
sinc
time
pasteur
genom
sequenc
reveal
muchawait
blueprint
pathogen
screen
blood
nucleic
acid
infecti
agent
blunt
spread
pathogen
transfus
field
antivir
therapeut
explod
technolog
develop
novel
safer
vaccin
becom
avail
quantum
jump
abil
detect
prevent
treat
infecti
diseas
result
improv
technolog
genom
moder
period
greatest
emerg
new
infecti
agent
ever
record
worrisom
increas
resist
exist
therapi
dozen
new
infecti
diseas
expect
emerg
come
decad
control
diseas
requir
better
understand
worldwid
threat
econom
burden
infecti
diseas
global
agenda
human
popul
shape
continu
interact
world
microb
textbook
document
plagu
athen
describ
thucydid
fifth
centuri
bc
european
bubon
plagu
kill
onethird
human
popul
repres
largest
epidem
ever
record
measl
smallpox
virus
introduc
american
contin
cort
contribut
disappear
aztec
civil
thousand
exampl
found
record
account
hundr
million
death
chang
cours
histori
select
expans
genet
diseas
thalassemia
defect
hemoglobin
provid
increas
resist
endem
malaria
twentieth
centuri
clean
water
vaccin
antimicrobi
therapi
brought
infecti
diseas
control
mark
one
greatest
achiev
civil
end
centuri
howev
infecti
agent
start
retali
seen
emerg
pathogen
resist
antimicrobi
new
pathogen
previous
detect
human
review
focu
major
chang
infecti
diseas
scientif
progress
field
last
decad
overview
princip
infecti
diseas
last
decad
show
divid
three
major
group
signific
progress
made
period
newli
emerg
impact
fig
box
consider
progress
last
decad
made
human
immunodefici
viru
hiv
hepat
c
viru
hcv
develop
countri
poliomyel
meningococc
pneumococc
diseas
campaign
erad
poliomyel
involv
vaccin
two
billion
children
reduc
global
incid
polio
case
per
year
less
period
fig
today
believ
diseas
erad
world
within
next
year
similarli
unit
state
introduct
conjug
vaccin
seven
serotyp
pneumococcu
decreas
incid
invas
pneumococc
diseas
less
case
per
peopl
proof
concept
conjug
vaccin
meningococcu
earli
made
possibl
introduct
conjug
vaccin
meningococcu
c
unit
kingdom
virtual
elimin
diseas
global
elimin
bacteri
mening
may
achiev
target
vaccin
meningococcu
acyw
b
becom
avail
within
next
decad
signific
progress
period
also
achiev
control
hcv
hiv
develop
countri
clone
hepat
c
genom
enabl
develop
diagnost
method
test
blood
blood
deriv
earli
result
reduct
new
hcv
case
per
year
per
year
unit
state
alon
fig
introduct
cocktail
drug
highli
activ
antiretrovir
therapi
haart
standard
care
peopl
hiv
transform
hiv
western
world
deadli
diseas
manag
chronic
diseas
also
worth
mention
diphtheria
cholera
two
diseas
reemerg
begin
control
period
fig
although
control
achiev
infect
unpreced
number
infecti
diseas
emerg
period
includ
avian
influenza
sever
acut
respiratori
syndrom
sar
west
nile
ebola
variant
creutzfeldtjakob
diseas
vcjd
last
decad
also
saw
increas
preval
antibioticresist
bacteria
reemerg
previous
erad
pathogen
agent
bioterror
fig
avian
influenza
report
infect
human
seven
time
h
r
c
l
p
e
r
p
e
c
v
e
last
seven
yearsth
last
outbreak
period
viru
first
reappear
hong
kong
strain
infect
human
caus
death
two
year
later
hong
kong
new
avian
viru
infect
two
peopl
viru
strain
caus
three
infect
one
death
wit
explos
new
case
case
death
report
seri
independ
outbreak
thailand
vietnam
far
outbreak
control
cull
million
fowl
multipl
independ
outbreak
last
two
year
suggest
proxim
new
flu
pandem
last
decad
also
saw
emerg
new
diseas
caus
transmiss
pathogen
anim
human
sar
coronaviru
short
period
februari
juli
infect
peopl
caus
death
fig
like
transmit
increas
contact
human
viruscarri
wild
anim
sold
food
asian
market
although
sar
outbreak
quickli
resolv
gener
widespread
panic
paralyz
travel
threaten
global
economi
diseas
anim
origin
emerg
past
decad
ebola
hemorrhag
fever
sever
independ
instanc
viru
transmiss
nonhuman
primat
hunter
caus
total
death
zair
republ
congo
gabon
variant
form
creutzfeldtjakob
diseas
vcjd
new
type
lethal
neurodegen
diseas
affect
young
peopl
previous
rare
decad
caus
case
fig
diseas
transmit
human
consumpt
meat
cow
infect
bovin
spongiform
enceph
bse
prion
west
nile
viru
flaviviru
describ
first
time
africa
endem
europ
central
asia
report
first
time
new
york
like
air
travel
respons
viru
cross
contin
viru
infect
bird
transmit
bird
mammal
urban
mosquito
culex
pipienswithin
four
year
viru
spread
across
unit
state
infect
peopl
caus
death
fig
anoth
worrisom
trend
past
year
increas
resist
bacteria
multipl
antibiot
figur
methicillinresist
staphylococcu
aureu
unit
kingdom
use
exampl
global
trend
repres
seriou
threat
hospit
patient
addit
methicillinresist
aureu
multipl
antibiot
resist
problem
also
streptococcu
pneumonia
enterococcu
faecali
pseudomona
aeruginosa
mycobacterium
tuberculosi
final
human
also
propag
use
microbi
pathogen
bioterror
day
septemb
terrorist
attack
new
york
anthrax
infect
ignit
deliber
releas
bacteri
spore
report
florida
although
powder
spore
deliv
mail
caus
total
infect
death
chang
forev
public
percept
microbi
pathogen
scientif
public
bioterror
increas
per
year
fig
smallpox
vaccin
start
first
time
stop
follow
erad
viru
final
fear
biolog
weapon
capabl
mass
destruct
motiv
begin
war
iraq
unfortun
shown
figur
last
decad
impact
three
diseas
alon
contribut
half
global
burden
infecti
diseas
mortal
tuberculosi
malaria
hiv
worldwid
inde
seen
volum
number
novemb
natur
medicin
ene
tuberculosi
malaria
immunocompromis
popul
infect
hiv
event
summar
figur
happen
field
parallel
revolut
progress
microbiolog
laboratori
sequenc
first
bacteri
genom
ref
subsequ
genom
revolut
repres
largest
chang
microbiolog
sinc
time
pasteur
less
decad
genom
provid
blueprint
microorgan
abil
explor
cultureindepend
manner
global
divers
live
organ
today
avail
public
databas
bacteri
genom
viral
genom
malaria
parasit
sequenc
incred
progress
consid
fewer
ten
year
ago
microbiologist
spent
research
effort
clone
sequenc
one
gene
time
addit
provid
inform
everi
gene
known
pathogen
genom
sequenc
facilit
research
old
infecti
agent
difficult
imposs
grow
vitro
hcv
bacillu
caus
whippl
diseas
instanc
hcv
grown
vitro
never
seen
electron
microscopi
imposs
studi
use
basic
technolog
convent
microbiolog
clone
genom
ref
allow
develop
diagnost
method
test
blood
blood
deriv
earli
virtual
elimin
new
transmiss
hcv
transfus
fig
addit
genom
sequenc
provid
inform
protein
need
make
viru
allow
express
recombin
viral
protein
use
develop
prophylact
therapeut
vaccin
test
antivir
compound
clinic
trial
sar
outbreak
genom
sequenc
becam
avail
less
month
identif
viru
immedi
enabl
develop
nucleic
acid
test
detect
viru
optim
measur
contain
spread
understand
probabl
anim
origin
design
therapeut
monoclon
antibodi
sever
effect
vaccin
move
toward
clinic
trial
sar
exampl
show
emerg
pathogen
identifi
sequenc
classifi
real
time
confirm
modern
technolog
effect
handl
unknown
emerg
infect
anoth
exampl
pathogen
escap
detect
convent
microbiolog
human
metapneumoviru
isol
first
time
nasopharyng
aspir
children
netherland
today
neg
rna
viru
paramyxovirida
famili
recogn
caus
acut
respiratori
infect
consid
respons
morbid
mortal
worldwid
togeth
respiratori
syncyti
viru
rsv
believ
caus
larg
fraction
sever
acut
respiratori
tract
infect
infant
elderli
immunocompromis
host
although
metapneumoviru
handl
convent
technolog
viru
probabl
miss
rather
difficult
grow
convent
cell
culturesmolecular
technolog
gene
hybrid
sequenc
instrument
facilit
identif
addit
better
detect
new
genomebas
technolog
complement
great
advanc
confoc
microscopi
fluoresc
protein
total
bodi
imag
microarray
number
anim
model
support
genet
techniqu
signaturetag
mutagenesi
vivo
express
technolog
enabl
studi
pathogen
interact
host
novel
approach
microbi
pathogenesi
new
disciplin
cellular
microbiolog
creat
differenti
modern
microbiolog
studi
pathogen
interact
host
nativ
environ
classic
microbiolog
studi
pathogen
grown
rich
media
artifici
condit
laboratori
new
approach
contribut
discoveri
virul
factor
necessari
pathogen
grown
laboratori
essenti
preferenti
express
vivo
infect
perhap
intrigu
among
bacteri
type
iii
type
iv
secret
system
molecular
syring
inject
protein
host
cell
facilit
infect
surviv
within
host
similarli
human
genom
cluster
human
popul
use
genet
tool
singl
nucleotid
polymorph
expect
provid
genet
basi
suscept
infecti
diseas
patholog
deriv
infect
expect
abl
predict
like
succumb
resist
infect
respond
therapi
vaccin
preliminari
exampl
may
becom
routin
futur
use
gene
express
profil
studi
gene
upregul
clinic
leprosi
defin
clinic
form
diseas
identif
gene
express
signatur
defin
success
vaccin
protect
infect
helicobact
pylori
pathogen
centuri
vaccin
develop
accord
pasteur
principl
isol
inactiv
inject
caus
microorgan
principl
provid
kill
live
attenu
subunit
vaccin
use
today
fig
respons
larg
part
control
infecti
diseas
achiev
date
pasteur
principl
allow
develop
vaccin
microorgan
cultiv
vitro
hcv
papillomaviru
type
lepra
also
principl
pasteur
provid
vaccin
antigen
hypervari
microorgan
serogroup
b
meningococcu
gonococcu
malaria
hiv
teach
induc
cytotox
cell
kill
infect
host
cell
therefor
contribut
control
viral
replic
last
decad
overcom
technic
limit
even
still
unabl
use
effect
enough
solv
challeng
hiv
avail
genom
allow
identif
novel
vaccin
candid
without
need
cultiv
microorgan
process
name
revers
vaccinolog
approach
genom
sequenc
viral
bacteri
parasit
pathogen
use
select
comput
analysi
microarray
proteom
genomebas
systemat
approach
antigen
like
confer
protect
immun
elimin
potenti
danger
antigen
show
homolog
human
protein
therefor
potenti
abl
induc
autoimmun
predict
antigen
express
recombin
dna
test
anim
model
genomebas
vaccin
approach
allow
develop
vaccin
hcv
human
papillomaviru
unabl
grow
vitro
approach
follow
principl
pasteur
genom
sequenc
becam
avail
use
predict
antigen
code
surfac
protein
hcv
vp
papillomaviru
express
develop
vaccin
present
phase
clinic
trial
respect
quot
exampl
revers
vaccinolog
meningococcu
b
end
appar
univers
meningococc
vaccin
beyond
reach
convent
vaccinolog
two
reason
first
polysaccharid
antigen
use
success
make
conjug
vaccin
meningococci
immunogen
inde
potenti
trigger
autoimmun
ident
self
antigen
second
best
proteinbas
vaccin
induc
immun
antigen
variabl
protein
shown
induc
protect
immun
mostli
strain
use
make
vaccin
without
substanti
crossprotect
case
sequenc
bacteri
genom
allow
comput
predict
approxim
novel
vaccin
candid
express
escherichia
coli
test
abil
elicit
protect
immun
remark
approach
identifi
novel
protect
antigen
conserv
meningococc
strain
test
clinic
trial
meningococcu
b
exampl
follow
mani
bacteri
pathogen
includ
pneumococcu
group
b
streptococcu
chlamydia
although
vaccin
avail
today
work
induc
antibodi
believ
conquer
difficult
diseas
hiv
malaria
chronic
diseas
cancer
may
requir
involv
tcell
arm
immun
system
period
sever
method
develop
induc
cytotox
tcell
respons
follow
vaccin
case
hiv
extens
proof
concept
obtain
nonhuman
primat
effect
stimul
cytotox
cell
abl
contain
viremia
effect
method
induc
cytotox
cell
nonhuman
primat
human
engin
nonrepl
viral
vector
modifi
vaccinia
ankara
mva
replicationincompet
adenovirus
dna
vaccin
mix
regim
dna
prime
follow
viral
vector
boost
shown
increas
cytotox
respons
success
induct
malariaspecif
cell
obtain
human
use
dnaprim
mva
boost
strategi
exampl
effect
protect
obtain
nonhuman
primat
adenovir
vector
onedos
vaccin
recent
describ
ebola
viru
one
surpris
decad
also
understand
live
organ
conserv
innat
immun
defens
pathogen
mediat
tolllik
receptor
nod
protein
sens
molecul
signatur
microb
dna
contain
unmethyl
cpg
sequenc
doublestrand
rna
lipopolysaccharid
etc
understand
molecular
basi
innat
immun
respons
provid
potenti
manipul
immun
system
repres
one
intrigu
develop
expect
next
decad
among
earli
result
new
area
develop
adjuv
base
unmethyl
cpg
motif
preval
bacteri
vertebr
genom
dna
seen
signatur
bacteri
infect
innat
immun
system
synthet
cpgcontain
oligonucleotid
shown
stimul
tolllik
receptor
induc
h
proinflammatori
cytokin
effect
adjuv
mani
vaccin
anim
model
preliminari
clinic
trial
figur
provid
exampl
predict
happen
field
vaccin
next
decad
revers
vaccinolog
dna
vaccin
nonrepl
vector
understand
innat
immun
system
develop
new
ration
design
adjuv
mucos
system
deliveri
vaccin
like
use
drive
develop
mani
novel
vaccin
prevent
treat
infecti
diseas
ultim
mention
safeti
vaccin
improv
enorm
last
decad
efficaci
vaccin
oral
polioviru
wholecel
pertussi
vaccin
remov
vaccin
schedul
western
countri
rare
perceiv
untoward
effect
replac
less
reactogen
vaccin
new
vaccin
base
technolog
deliv
vaccin
high
standard
safeti
largescal
screen
natur
compound
abl
kill
bacteria
vitro
basi
boom
antibiot
success
antivir
fact
wherea
bacteria
distinct
freeliv
organ
target
drug
virus
parasit
entiti
invad
healthi
host
cell
hijack
reproduct
machineri
make
difficult
kill
virus
without
also
kill
cell
infiltr
first
antivir
describ
four
licens
amantadin
ribavirin
acyclovir
deriv
azt
influenza
rsv
herp
hiv
respect
sinc
new
antivir
approv
combat
hiv
other
combat
hepat
b
viru
hcv
influenza
herp
fig
drive
forc
boom
antivir
period
pressur
contain
hiv
pandem
combin
increas
understand
molecular
mechan
viral
life
cycl
allow
identif
new
target
therapeut
intervent
begin
hiv
grow
us
worldwid
us
new
hiv
case
death
record
grow
respect
fig
worldwid
million
case
million
fig
first
effect
therapi
hiv
came
approv
first
combin
revers
transcriptas
inhibitor
azt
ddc
prevent
viral
dna
synthesi
act
chain
termin
approv
safer
inhibitor
revers
transcriptas
first
proteas
inhibitor
togeth
abil
use
polymeras
chain
reaction
measur
amount
viru
present
given
volum
blood
viral
load
allow
introduct
cocktail
drug
standard
care
peopl
hiv
haart
increas
life
expect
transform
hiv
western
world
deadli
diseas
manag
chronic
diseas
postpon
unfortun
solv
hiv
problem
new
infect
death
hiv
start
plateau
decreas
first
time
today
unit
state
approxim
new
case
death
per
year
number
peopl
live
hiv
increas
dramat
fig
box
current
longterm
solut
manag
popul
chronic
infect
hiv
provid
new
challeng
continu
develop
new
antivir
activ
resist
hiv
isol
select
present
therapi
control
side
effect
result
chronic
treatment
today
target
enzym
develop
antivir
compound
viral
enzym
necessari
replic
viral
genom
retrovir
revers
transcriptas
dna
rnadepend
polymeras
helicas
proteas
necessari
cleav
viral
polyprotein
influenza
neuraminidas
necessari
releas
viru
cell
even
cellular
enzym
involv
gener
nucleotid
pool
inosin
deydrogenas
unknown
reason
import
viral
replic
avail
valid
target
enzym
use
highthroughput
screen
natur
combinatori
librari
today
complement
abil
cocryst
target
protein
inhibitor
allow
use
structurebas
drug
design
gener
optim
better
lead
recent
understand
molecular
mechan
viral
entri
host
cell
allow
develop
new
class
antivir
compound
known
fusion
inhibitor
one
enfuvirtid
alreadi
use
therapi
aid
enfurvitid
synthet
peptid
bind
region
envelop
prevent
conform
chang
necessari
drive
fusion
viral
membran
host
cell
effect
vitro
although
yet
clinic
relev
small
interf
rna
sirna
doublestrand
rna
oligonucleotid
use
celldefens
enzym
pathway
drive
select
degrad
viral
rna
product
sirna
shown
effect
vitro
virtual
medic
import
virus
includ
hiv
hcv
howev
develop
drug
need
meet
challeng
deliv
effect
larg
unstabl
molecul
oligonucleotid
infect
tissu
conclus
wherea
antibiot
hot
drug
past
centuri
antivir
hot
drug
twentyfirst
centuri
time
expect
effect
drug
viral
infect
treatment
infecti
diseas
made
quantum
leap
behr
kitasato
discov
immun
low
dose
steril
cultur
supernat
tetanu
diphtheria
induc
sera
transfer
anim
could
cure
symptom
diseas
follow
centuri
sera
one
import
lifesav
tool
treat
bacteri
infect
diphtheria
tetanu
anthrax
botul
pneumococc
diseas
viral
infect
rabi
anim
sera
larg
disappear
antiinfect
toolbox
last
year
mostli
toxic
reaction
serum
sick
caus
inject
human
hors
sera
decreas
popular
blood
deriv
reduc
use
human
gammaglobulin
applic
cytomegaloviru
parvoviru
develop
technolog
commerci
human
monoclon
antibodi
human
mous
antibodi
allow
licensur
first
human
monoclon
antibodi
neutral
rsv
vitro
prevent
rsv
infect
newborn
increas
global
prioriti
global
threat
econom
burden
infecti
diseas
need
visibl
public
policymak
develop
develop
countri
develop
countri
need
awar
although
spend
enough
money
prevent
cost
high
scientist
media
need
make
effort
improv
effect
commun
infecti
diseas
receiv
high
prioriti
polit
econom
agenda
everi
countri
world
global
legisl
collabor
sar
hiv
avian
influenza
clearli
shown
whatev
happen
one
part
world
may
quickli
becom
global
problem
intern
law
regul
infecti
diseas
implement
intern
team
power
overse
global
interest
local
concern
promot
effect
intern
collabor
place
coordin
regulatori
agenc
agenc
regul
human
health
anim
health
trade
hunt
food
travel
far
act
independ
need
talk
coordin
action
seen
one
exampl
bse
sar
decis
one
agenc
result
strong
implic
spread
infecti
diseas
area
vaccin
studi
develop
licens
infecti
agent
includ
econom
uninterest
smallpox
avian
influenza
shown
orphan
infecti
agent
becom
global
interest
time
problem
late
develop
measur
control
sustain
econom
system
must
develop
sustain
system
protect
health
world
popul
publicpriv
partnership
global
fund
gate
foundat
shortterm
seem
best
way
make
rapid
progress
trigger
enorm
progress
never
seen
longterm
global
health
reli
good
chariti
born
still
licens
human
antibodi
infecti
diseas
high
dose
requir
mgkg
mgadult
person
expens
make
administr
impract
adult
recent
new
technolog
effici
clone
human
memori
b
cell
infect
immun
peopl
may
transform
field
technolog
allow
screen
highaffin
human
monoclon
antibodi
virus
isol
clone
produc
antibodi
may
abl
therapeut
effect
mgkg
make
industri
develop
possibl
therefor
expect
human
monoclon
antibodi
becom
increasingli
import
tool
passiv
prevent
therapi
infecti
diseas
avail
sequenc
viral
bacteri
parasit
genom
provid
inform
necessari
express
recombin
microbi
antigen
could
use
detect
antibodi
patient
sera
develop
specif
assay
base
nucleic
acid
amplif
technolog
abl
directli
detect
genom
copi
infecti
agent
new
technolog
allow
time
respons
emerg
new
pathogen
case
sar
develop
assay
monitor
control
spread
infecti
agent
virtual
elimin
seriou
infect
transmit
blood
transfus
one
mileston
histori
medicin
achiev
last
decad
made
possibl
technolog
fig
earli
risk
infect
hiv
hcv
blood
transfus
rang
introduct
screen
antibodi
hiv
hcv
tremend
increas
safeti
blood
blood
product
reduc
risk
less
final
introduct
nucleic
acid
test
allow
detect
recent
infect
donor
time
yet
develop
antibodi
reduc
risk
one
two
million
encourag
dramat
success
test
blood
hiv
hcv
new
assay
recent
introduc
test
blood
hepat
b
west
nile
virus
virtual
elimin
common
diseas
transmit
blood
transfus
similar
technolog
appli
detect
infecti
agent
parvoviru
malaria
leishmania
vcjd
pathogen
bacteria
agent
spread
bioterrorist
late
optim
deriv
success
vaccin
antibiot
gener
belief
infecti
diseas
conquer
longer
problem
human
know
optim
prematur
infecti
diseas
stay
inde
human
histori
never
seen
mani
new
infecti
diseas
recent
time
shotgun
sequenc
microorgan
captur
filter
hundr
liter
water
sargasso
sea
identifi
million
new
gene
speci
novel
bacteri
phylotyp
show
microbi
divers
order
magnitud
larger
previous
estim
impli
environ
anim
world
huge
reservoir
microb
appropri
circumst
may
recombin
jump
speci
gener
new
human
pathogen
modern
societi
provid
fertil
environ
happen
acceler
chang
human
behavior
ecosystem
continu
disturb
equilibrium
microb
host
expos
new
environ
behavior
unpredict
sometim
result
diseas
factor
involv
increas
global
popul
overcrowd
citi
increas
travel
intens
anim
farm
food
product
sexual
practic
poverti
global
warm
breakdown
public
health
measur
believ
human
primarili
respons
infecti
diseas
zoonos
anim
infect
transfer
man
promot
human
behavior
fig
tabl
bushmeat
hunt
ebola
probabl
hiv
sale
live
wild
anim
open
market
sar
intens
farm
sale
differ
speci
next
open
market
avian
influenza
find
favor
environ
open
market
asia
migratori
aquat
bird
influenza
viru
grow
without
caus
diseas
sold
next
chicken
pig
cultiv
expand
enorm
feed
grow
asian
popul
therefor
easi
predict
next
decad
see
dozen
new
infecti
agent
emerg
human
question
whether
contain
caus
new
global
pandem
hiv
influenza
black
death
middl
age
caus
sever
dozen
million
death
destroy
economi
societi
today
compel
new
threat
seem
avian
influenza
multipl
independ
outbreak
last
two
antibiot
resist
widespread
use
avail
antibiot
year
introduct
avail
spread
environ
class
antibiot
year
involv
sever
differ
viru
strain
outbreak
asia
canada
netherland
dire
warn
new
flu
pandem
howev
imposs
predict
viru
go
caus
go
happen
fortun
today
technolog
provid
adequ
tool
detect
manag
control
prevent
emerg
infect
technolog
suffici
contain
impact
infecti
diseas
like
fail
unless
govern
increas
prioriti
infecti
diseas
polit
agenda
promot
coordin
collabor
global
action
develop
develop
countri
list
measur
necessari
global
control
infecti
diseas
includ
increas
global
prioriti
global
legisl
collabor
coordin
regulatori
agenc
develop
vaccin
prevent
diseas
sustain
econom
system
support
initi
box
exampl
show
effect
global
approach
repres
campaign
erad
poliomyel
largest
public
health
initi
ever
tri
launch
south
america
taken
world
assembl
govern
bodi
world
health
organ
commit
global
erad
polioviru
year
period
two
billion
children
immun
use
nation
immun
day
budget
approxim
four
billion
progress
toward
erad
viru
fast
countri
contin
report
endem
polioviru
american
contin
western
pacif
region
european
region
respect
certifi
polio
free
three
year
without
case
polio
six
polioendem
countri
report
niger
nigeria
egypt
africa
india
afghanistan
pakistan
asia
period
case
reduc
less
fig
unfortun
viru
import
countri
eight
african
countri
previous
polio
free
although
polio
erad
miss
deadlin
year
seen
setback
initi
one
best
exampl
global
effort
within
short
period
time
reduc
incid
infecti
diseas
final
effort
remain
endem
region
elimin
diseas
world
within
next
year
leav
us
problem
whether
long
continu
vaccin
diseas
longer
exist
hope
success
polio
catalyst
trigger
similar
global
prioriti
collabor
infecti
diseas
